Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

科跃奇 - NMPA Drug Approval Details

Approvals/NMPA/Recombinant Coagulation Factor VIII for Injection

Approved

生物制品

Recombinant Coagulation Factor VIII for Injection

BAYER HEALTHCARE LLC🇨🇳 National Medical Products Administration

Approval Date: Jan 20, 2023
Approval ID: ecbc7d9136f2f210
Company: BAYER HEALTHCARE LLC
Type: 生物制品

Approval Details

Approval Id: ecbc7d9136f2f210
Approval Number: 国药准字SJ20180017
Generic Name: 注射用重组人凝血因子Ⅷ
Generic Name En: Recombinant Coagulation Factor VIII for Injection
Trade Name: 科跃奇
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 500IU/瓶
Reg Date: 2023-01-20
Expired Date: 2028-01-19
Company Name: BAYER HEALTHCARE LLC
Production Company Name: BAYER HEALTHCARE LLC
Company Detail Path: /organization/bayer-healthcare-llc
Production Company Detail Path: /organization/bayer-healthcare-llc

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jan 20, 2023

Approval ID

ecbc7d9136f2f210

Type

生物制品

Back to NMPA Approvals